Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00700336 · OUTCOME

4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) · Source last updated 2021-07-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
End of study

What was measured

Planned: Forty-two patients were to be treated in Arm A. If ≥ 23 patients (\>54%) were free of progression and death at 4 months, then the study regimen would be considered for further evaluation in this indication.

Groups in this outcome

Pemetrexed, Cisplatin, and CBP501

Pemetrexed, Cisplatin, and CBP501 administered once every 3 weeks

Pemetrexed and Cisplatin

Pemetrexed and Cisplatin every three weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pemetrexed, Cisplatin, and CBP50140
Pemetrexed and Cisplatin23

Reported measurements

4M PFS by Independent Image Review
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pemetrexed, Cisplatin, and CBP50125Not reportedNot reportedNot reportedNot reported
Pemetrexed and Cisplatin9Not reportedNot reportedNot reportedNot reported
4M PFS by Site assess
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pemetrexed, Cisplatin, and CBP50127Not reportedNot reportedNot reportedNot reported
Pemetrexed and Cisplatin13Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        25
      2. group Id
        OG001
        value
        9
    title
    4M PFS by Independent Image Review
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        27
      2. group Id
        OG001
        value
        13
    title
    4M PFS by Site assess
denoms
  1. counts
    1. group Id
      OG000
      value
      40
    2. group Id
      OG001
      value
      23
    units
    Participants
description
Planned: Forty-two patients were to be treated in Arm A. If ≥ 23 patients (\>54%) were free of progression and death at 4 months, then the study regimen would be considered for further evaluation in this indication.
groups
  1. description
    Pemetrexed, Cisplatin, and CBP501 administered once every 3 weeks
    id
    OG000
    title
    Pemetrexed, Cisplatin, and CBP501
  2. description
    Pemetrexed and Cisplatin every three weeks
    id
    OG001
    title
    Pemetrexed and Cisplatin
param Type
NUMBER
reporting Status
POSTED
time Frame
End of study
title
4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice